Svetlana Reilly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Svetlana Reilly has a total of 271 co-authors. Here are the top co-authors by number of shared publications:
- Rana Sayeed
Cardiothoracic Surgery, Oxford Heart Centre, John Radcliffe Hospital, Oxford, UK
10 shared publications Barbara Casadei
Division of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
9 shared publications- Keith Michael Channon
Division of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, John Radcliffe Hospital, Oxford, UK
9 shared publications George Krasopoulos
Cardiothoracic Surgery, Oxford Heart Centre, John Radcliffe Hospital, Oxford, UK
6 shared publications- Stanley Nattel
Montreal Heart Institute , Montreal, Quebec
6 shared publications - Barbara Casadei
Imperial College London
5 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (11) , 1231-1249
Selective blockade of microRNA-31-5p−calcitonin receptor interaction reverses established atrial fibrosis and atrial arrhythmia burden
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is promoted by atrial fibrosis, a form of structural remodelling for which effective therapies are lacking. MicroRNA-31-5p (miR-31-5p), an aging-associated, atrial-enriched microRNA, has been linked to AF, but its role in atrial fibrosis is unknown. Here we show that atrial fibroblasts from patients with persistent AF exhibit increased miR-31-5p expression and reduced expression of the calcitonin receptor (CTR, encoded by CALCR ). MiR-31-5p directly represses CTR and promotes pro-fibrotic fibroblast responses, whereas its inhibition restores CTR expression. Fibroblast-specific overexpression of miR-31 in mice reduces atrial CTR expression, increases atrial fibrosis and enhances arrhythmia susceptibility. Selective disruption of miR-31-5p− CALCR binding using a locked nucleic acid target site blocker restores atrial CTR expression, prevents fibrosis progression and reduces arrhythmia burden. In mice with established atrial remodeling, this strategy promotes fibrosis regression, identifying the miR-31-5p−CTR axis as a potential therapeutic target in AF.
- 30 October 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (11) , 1231-1249
Open AccessSelective blockade of microRNA-31-5p−calcitonin receptor interaction reverses established atrial fibrosis and atrial arrhythmia burden
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is promoted by atrial fibrosis, a form of structural remodelling for which effective therapies are lacking. MicroRNA-31-5p (miR-31-5p), an aging-associated, atrial-enriched microRNA, has been linked to AF, but its role in atrial fibrosis is unknown. Here we show that atrial fibroblasts from patients with persistent AF exhibit increased miR-31-5p expression and reduced expression of the calcitonin receptor (CTR, encoded by CALCR ). MiR-31-5p directly represses CTR and promotes pro-fibrotic fibroblast responses, whereas its inhibition restores CTR expression. Fibroblast-specific overexpression of miR-31 in mice reduces atrial CTR expression, increases atrial fibrosis and enhances arrhythmia susceptibility. Selective disruption of miR-31-5p− CALCR binding using a locked nucleic acid target site blocker restores atrial CTR expression, prevents fibrosis progression and reduces arrhythmia burden. In mice with established atrial remodeling, this strategy promotes fibrosis regression, identifying the miR-31-5p−CTR axis as a potential therapeutic target in AF.
- Open Access
- 22 September 2026
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 11 (11)
Cardiac Fibrosis as a Dynamic Therapeutic Target
- 22 September 2026
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 11 (11)
Open AccessCardiac Fibrosis as a Dynamic Therapeutic Target
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Impaired Branched-Chain Amino Acid Catabolism Drives Peritoneal Fibrosis through Branched-Chain α-Ketoacid–Mediated Suppression of the Pentose Phosphate Pathway
Key Points: Impaired branched-chain amino acid catabolism was identified as a metabolic hallmark of peritoneal fibrosis. Branched-chain α ketoacid burden, rather than the amino acids, more closely tracked with and functionally contributed to fibrotic responses. Branched-chain α ketoacid burden was linked to reduced pentose phosphate pathway–associated redox capacity and amplified fibrotic responses. Background: Peritoneal dialysis (PD) is a life-sustaining therapy for kidney failure, yet its long-term viability is compromised by progressive peritoneal fibrosis in some patients. Currently, reliable treatment options are lacking because the pathogenesis remains poorly understood, with the metabolic underpinnings of fibrotic progression remaining particularly elusive. Methods: Using a physiologically relevant framework comprising human primary mesothelial cells and a PD fluid– exposed mouse model, we performed bidirectional genetic and pharmacological modulation of branched-chain amino acid catabolism. Integrated proteomic and metabolomic analyses were conducted to investigate downstream metabolic consequences. Results: We identified profound impairment in branched-chain amino acid (BCAA) catabolism, centered on a functional bottleneck at the rate-limiting branched-chain α -ketoacid dehydrogenase complex, as a metabolic hallmark of peritoneal fibrosis. Functional uncoupling of the amino acids from their ketoacid derivatives indicated that branched-chain α -ketoacid (BCKA) burden was more closely linked to the fibrotic phenotype than BCAA abundance alone. Mechanistically, BCKA burden was associated with reduced glucose-6-phosphate dehydrogenase expression and activity, lower reduced NAD phosphate–generating capacity, and increased intracellular oxidant burden. Conclusions: Together, these findings showed that BCKA burden, rather than BCAA abundance alone, more closely tracked fibrotic responses and was linked to reduced pentose phosphate pathway–associated redox capacity in peritoneal fibrosis.
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Impaired Branched-Chain Amino Acid Catabolism Drives Peritoneal Fibrosis through Branched-Chain α-Ketoacid–Mediated Suppression of the Pentose Phosphate Pathway
Key Points: Impaired branched-chain amino acid catabolism was identified as a metabolic hallmark of peritoneal fibrosis. Branched-chain α ketoacid burden, rather than the amino acids, more closely tracked with and functionally contributed to fibrotic responses. Branched-chain α ketoacid burden was linked to reduced pentose phosphate pathway–associated redox capacity and amplified fibrotic responses. Background: Peritoneal dialysis (PD) is a life-sustaining therapy for kidney failure, yet its long-term viability is compromised by progressive peritoneal fibrosis in some patients. Currently, reliable treatment options are lacking because the pathogenesis remains poorly understood, with the metabolic underpinnings of fibrotic progression remaining particularly elusive. Methods: Using a physiologically relevant framework comprising human primary mesothelial cells and a PD fluid– exposed mouse model, we performed bidirectional genetic and pharmacological modulation of branched-chain amino acid catabolism. Integrated proteomic and metabolomic analyses were conducted to investigate downstream metabolic consequences. Results: We identified profound impairment in branched-chain amino acid (BCAA) catabolism, centered on a functional bottleneck at the rate-limiting branched-chain α -ketoacid dehydrogenase complex, as a metabolic hallmark of peritoneal fibrosis. Functional uncoupling of the amino acids from their ketoacid derivatives indicated that branched-chain α -ketoacid (BCKA) burden was more closely linked to the fibrotic phenotype than BCAA abundance alone. Mechanistically, BCKA burden was associated with reduced glucose-6-phosphate dehydrogenase expression and activity, lower reduced NAD phosphate–generating capacity, and increased intracellular oxidant burden. Conclusions: Together, these findings showed that BCKA burden, rather than BCAA abundance alone, more closely tracked fibrotic responses and was linked to reduced pentose phosphate pathway–associated redox capacity in peritoneal fibrosis.
- Open Access
- 22 June 2026
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 11 (6) , 101598
Adipose–Cardiac Crosstalk in Obesity-Related Atrial Fibrillation
- 22 June 2026
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 11 (6) , 101598
Open AccessAdipose–Cardiac Crosstalk in Obesity-Related Atrial Fibrillation
- Open Access
Association of Circulating Calcitonin With Risk and Onset of Postoperative Atrial Fibrillation After Cardiac Surgery
Background: Postoperative atrial fibrillation (POAF) affects up to 50% of cardiac surgery patients and is linked to higher morbidity, longer hospital stays and increased thromboembolic risk. Early identification of at-risk patients remains challenging. Calcitonin (CT), a hormone with anti-fibrotic effects, may serve as a novel biomarker. Methods: In 491 patients undergoing elective cardiac surgery, baseline serum CT was measured preoperatively using CT-specific enzyme-linked immunosorbent assay (ELISA). Patients with pre-existing AF were excluded. Associations between CT levels and POAF incidence and onset were evaluated using logistic regression, Cox proportional hazards models, and Kaplan–Meier analysis. Results: Among 248 patients with detectable CT levels, 88 patients developed POAF. Higher baseline CT was independently associated with lower risk of POAF (OR 0.68 per 5 pg/ml increase; 95% CI 0.51-0.89; P = 0.009) and delayed arrhythmia onset (adjusted HR 0.941; 95% CI 0.898-0.980, P = 0.0026) after adjusting for covariates. Kaplan–Meier analysis demonstrated a graded relationship between increasing CT levels and reduced cumulative incidence of POAF. In this cohort, baseline CT showed greater discriminative ability than CRP and BNP, although overall model performance remained moderate. Conclusion: Higher preoperative circulating CT levels are associated with reduced risk and delayed onset of POAF following cardiac surgery. These findings suggest that calcitonin may have the potential as a biomarker for perioperative risk stratification in POAF. Given the observational design and single-centre setting, further validation in independent cohorts and studies integrating mechanistic insights are warranted.
Open AccessAssociation of Circulating Calcitonin With Risk and Onset of Postoperative Atrial Fibrillation After Cardiac Surgery
Background: Postoperative atrial fibrillation (POAF) affects up to 50% of cardiac surgery patients and is linked to higher morbidity, longer hospital stays and increased thromboembolic risk. Early identification of at-risk patients remains challenging. Calcitonin (CT), a hormone with anti-fibrotic effects, may serve as a novel biomarker. Methods: In 491 patients undergoing elective cardiac surgery, baseline serum CT was measured preoperatively using CT-specific enzyme-linked immunosorbent assay (ELISA). Patients with pre-existing AF were excluded. Associations between CT levels and POAF incidence and onset were evaluated using logistic regression, Cox proportional hazards models, and Kaplan–Meier analysis. Results: Among 248 patients with detectable CT levels, 88 patients developed POAF. Higher baseline CT was independently associated with lower risk of POAF (OR 0.68 per 5 pg/ml increase; 95% CI 0.51-0.89; P = 0.009) and delayed arrhythmia onset (adjusted HR 0.941; 95% CI 0.898-0.980, P = 0.0026) after adjusting for covariates. Kaplan–Meier analysis demonstrated a graded relationship between increasing CT levels and reduced cumulative incidence of POAF. In this cohort, baseline CT showed greater discriminative ability than CRP and BNP, although overall model performance remained moderate. Conclusion: Higher preoperative circulating CT levels are associated with reduced risk and delayed onset of POAF following cardiac surgery. These findings suggest that calcitonin may have the potential as a biomarker for perioperative risk stratification in POAF. Given the observational design and single-centre setting, further validation in independent cohorts and studies integrating mechanistic insights are warranted.
- Open Access
Integrated Cardiac and Circulating N-glycan Signatures Reflect Atrial Remodeling in Patients with Atrial Fibrillation
Background: Atrial adverse remodeling drives the maintenance and progression of atrial fibrillation (AF) through electrical and structural myocardial changes, often accompanied by inflammation. Circulating N-glycans are emerging as biomarkers in inflammatory diseases, yet their role in AF remains undefined. Methods: We profiled the serum N-glycome of 138 patients with AF, non-AF arrhythmias, or sinus rhythm (SR) controls from peripheral venous (PV) and coronary sinus (CS) samples using hydrophilic interaction liquid chromatography coupled with high-resolution mass spectrometry. Glycan traits associated with AF were identified via logistic regression adjusted for clinical risk factors. Multivariate glycan scores were derived from PV and CS datasets using LASSO regression. In a subset (N=37), plasma proteome profiling was performed with the Olink Reveal panel. Results: Sixty-two glycan peaks were detected; 27 in PV and 8 in CS serum differed significantly between AF and controls. PV and CS glycan scores accurately classified AF, with the PV score correlating with 11 plasma proteins linked to structural remodeling and thrombo-inflammatory processes. The most abundant glycan, A2G2S2 (peak 30), was associated with higher odds of AF after adjusting for confounders (OR 2.22 [95% CI: 1.40–3.75], P = 0.001). CS A2G2S2 correlated with C-reactive protein (R = 0.432, P = 0.0275) and was elevated in patients with left atrial enlargement (P = 0.0354), but unchanged in those with impaired left ventricular ejection fraction or hypertrophy. Conclusion: Integrated profiling of peripheral and cardiac serum identifies novel N-glycosylation signatures in AF. Specific cardiac and circulating N-glycan signatures, including A2G2S2, are associated with AF and reflect inflammation-driven atrial remodeling, highlighting potential mechanistic pathways and biomarker applications.
Open AccessIntegrated Cardiac and Circulating N-glycan Signatures Reflect Atrial Remodeling in Patients with Atrial Fibrillation
Background: Atrial adverse remodeling drives the maintenance and progression of atrial fibrillation (AF) through electrical and structural myocardial changes, often accompanied by inflammation. Circulating N-glycans are emerging as biomarkers in inflammatory diseases, yet their role in AF remains undefined. Methods: We profiled the serum N-glycome of 138 patients with AF, non-AF arrhythmias, or sinus rhythm (SR) controls from peripheral venous (PV) and coronary sinus (CS) samples using hydrophilic interaction liquid chromatography coupled with high-resolution mass spectrometry. Glycan traits associated with AF were identified via logistic regression adjusted for clinical risk factors. Multivariate glycan scores were derived from PV and CS datasets using LASSO regression. In a subset (N=37), plasma proteome profiling was performed with the Olink Reveal panel. Results: Sixty-two glycan peaks were detected; 27 in PV and 8 in CS serum differed significantly between AF and controls. PV and CS glycan scores accurately classified AF, with the PV score correlating with 11 plasma proteins linked to structural remodeling and thrombo-inflammatory processes. The most abundant glycan, A2G2S2 (peak 30), was associated with higher odds of AF after adjusting for confounders (OR 2.22 [95% CI: 1.40–3.75], P = 0.001). CS A2G2S2 correlated with C-reactive protein (R = 0.432, P = 0.0275) and was elevated in patients with left atrial enlargement (P = 0.0354), but unchanged in those with impaired left ventricular ejection fraction or hypertrophy. Conclusion: Integrated profiling of peripheral and cardiac serum identifies novel N-glycosylation signatures in AF. Specific cardiac and circulating N-glycan signatures, including A2G2S2, are associated with AF and reflect inflammation-driven atrial remodeling, highlighting potential mechanistic pathways and biomarker applications.
- Open Access
Longitudinal Plasma Proteome Changes Before and After Catheter Ablation in Atrial Fibrillation
Background: Proteins in human plasma serve as critical markers for predicting disease risk and guiding therapeutic development. Current prediction models for atrial fibrillation (AF) largely rely on electronic health records; however, the plasma proteome of patients with AF reflects key biological processes, including inflammation, that are not captured by clinical variables alone. Circulating inflammatory mediators contribute to electrical and structural remodelling in the atria, thereby sustaining the AF phenotype. Identification of plasma proteins associated with AF may therefore improve understanding of the inflammatory and other biological processes underlying AF pathophysiology. Objective: In this study, we profiled the plasma proteome of patients with paroxysmal AF (pxAF), persistent AF (persAF), and non-AF controls using Olink assay technology. Methods: Plasma samples from 30 individuals were analysed with the Olink Reveal panel. Differential expression analysis of normalised protein expression (NPX) values was performed between groups, with differentially expressed proteins (DEPs) defined by P < 0.05. Results: We identified 87 DEPs in pxAF and 107 DEPs in persAF compared with controls. From these, we shortlisted 11 candidate proteins that were upregulated in persAF at baseline and showed reduced expression 12 months after catheter ablation. This subset of proteins is implicated in the regulation of inflammation (CCL23, CXCL10, IL33), metabolism (ALDH3A1, NDUFS6), cell-matrix adhesion (AFAP1L1, LGALS7, SPOCK1), and physiological signalling (NOS1, PROK1, PTH). Conclusion: Collectively, these plasma proteins highlight systemic molecular mechanisms contributing to AF pathogenesis and represent potential AF-specific biomarkers warranting further investigation in larger clinical cohorts and mechanistic studies.
Open AccessLongitudinal Plasma Proteome Changes Before and After Catheter Ablation in Atrial Fibrillation
Background: Proteins in human plasma serve as critical markers for predicting disease risk and guiding therapeutic development. Current prediction models for atrial fibrillation (AF) largely rely on electronic health records; however, the plasma proteome of patients with AF reflects key biological processes, including inflammation, that are not captured by clinical variables alone. Circulating inflammatory mediators contribute to electrical and structural remodelling in the atria, thereby sustaining the AF phenotype. Identification of plasma proteins associated with AF may therefore improve understanding of the inflammatory and other biological processes underlying AF pathophysiology. Objective: In this study, we profiled the plasma proteome of patients with paroxysmal AF (pxAF), persistent AF (persAF), and non-AF controls using Olink assay technology. Methods: Plasma samples from 30 individuals were analysed with the Olink Reveal panel. Differential expression analysis of normalised protein expression (NPX) values was performed between groups, with differentially expressed proteins (DEPs) defined by P < 0.05. Results: We identified 87 DEPs in pxAF and 107 DEPs in persAF compared with controls. From these, we shortlisted 11 candidate proteins that were upregulated in persAF at baseline and showed reduced expression 12 months after catheter ablation. This subset of proteins is implicated in the regulation of inflammation (CCL23, CXCL10, IL33), metabolism (ALDH3A1, NDUFS6), cell-matrix adhesion (AFAP1L1, LGALS7, SPOCK1), and physiological signalling (NOS1, PROK1, PTH). Conclusion: Collectively, these plasma proteins highlight systemic molecular mechanisms contributing to AF pathogenesis and represent potential AF-specific biomarkers warranting further investigation in larger clinical cohorts and mechanistic studies.
- Open Access
- 7 January 2026
- Published by Springer Nature in Research Square
Selective blockade of microRNA-31-5p/calcitonin receptor interaction reverses established atrial fibrosis and atrial arrhythmia substrate
Atrial fibrillation (AF), the commonest cardiac arrhythmia, is a major contributor to mortality and morbidity. Atrial tissue fibrosis, a hallmark of structural remodelling in AF, is currently incurable and significantly hinders AF-treatment. MicroRNA(miR)-31 is linked to ageing (a key risk factor for AF). Here, we show that AF-patients are characterised by upregulation of miR-31-5p in atrial cardiofibroblasts that negatively regulates the calcitonin receptor (CTR), thereby promoting atrial fibrogenesis and arrhythmia. Specific blockade of miR-31-5p/CTR-mRNA binding with LNA-miRNA-Target-Site-Blocker selectively increases atrial CTR expression and reverses advanced atrial fibrosis and arrhythmogenesis in vivo. These findings suggest a key role for miR-31-5p/CTR binding in promoting atrial fibrosis and arrhythmogenesis, and represents a first example of an RNA-based therapeutic capable of reversing established fibrosis that forms an AF substrate. *Jasha Trompf, Kathryn Cox, and Mohit Hulsurkar contributed equally to this work.
- 7 January 2026
- Published by Springer Nature in Research Square
Open AccessSelective blockade of microRNA-31-5p/calcitonin receptor interaction reverses established atrial fibrosis and atrial arrhythmia substrate
Atrial fibrillation (AF), the commonest cardiac arrhythmia, is a major contributor to mortality and morbidity. Atrial tissue fibrosis, a hallmark of structural remodelling in AF, is currently incurable and significantly hinders AF-treatment. MicroRNA(miR)-31 is linked to ageing (a key risk factor for AF). Here, we show that AF-patients are characterised by upregulation of miR-31-5p in atrial cardiofibroblasts that negatively regulates the calcitonin receptor (CTR), thereby promoting atrial fibrogenesis and arrhythmia. Specific blockade of miR-31-5p/CTR-mRNA binding with LNA-miRNA-Target-Site-Blocker selectively increases atrial CTR expression and reverses advanced atrial fibrosis and arrhythmogenesis in vivo. These findings suggest a key role for miR-31-5p/CTR binding in promoting atrial fibrosis and arrhythmogenesis, and represents a first example of an RNA-based therapeutic capable of reversing established fibrosis that forms an AF substrate. *Jasha Trompf, Kathryn Cox, and Mohit Hulsurkar contributed equally to this work.
- Open Access
- 25 March 2025
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 4 (4) , 433-444
Single-nucleus multi-omics implicates androgen receptor signaling in cardiomyocytes and NR4A1 regulation in fibroblasts during atrial fibrillation
The dysregulation of gene expression programs in the human atria during persistent atrial fibrillation (AF) is not completely understood. Here, we reanalyze bulk RNA-sequencing datasets from two studies (N = 242) and identified 755 differentially expressed genes in left atrial appendages of individuals with persistent AF and non-AF controls. We combined the bulk RNA-sequencing differentially expressed genes with a left atrial appendage single-nucleus multi-omics dataset to assign genes to specific atrial cell types. We found noncoding genes at the IFNG locus (LINC01479, IFNG-AS1) strongly dysregulated in cardiomyocytes. We defined a gene expression signature potentially driven by androgen receptor signaling in cardiomyocytes from individuals with AF. Cell-type-specific gene expression modules suggested an increase in T cell and a decrease in adipocyte and neuronal cell gene expression in AF. Lastly, we showed that reducing NR4A1 expression, a marker of a poorly characterized human atrial fibroblast subtype, fibroblast activation markers, extracellular matrix remodeling and cell proliferation decreased.
- 25 March 2025
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 4 (4) , 433-444
Open AccessSingle-nucleus multi-omics implicates androgen receptor signaling in cardiomyocytes and NR4A1 regulation in fibroblasts during atrial fibrillation
The dysregulation of gene expression programs in the human atria during persistent atrial fibrillation (AF) is not completely understood. Here, we reanalyze bulk RNA-sequencing datasets from two studies (N = 242) and identified 755 differentially expressed genes in left atrial appendages of individuals with persistent AF and non-AF controls. We combined the bulk RNA-sequencing differentially expressed genes with a left atrial appendage single-nucleus multi-omics dataset to assign genes to specific atrial cell types. We found noncoding genes at the IFNG locus (LINC01479, IFNG-AS1) strongly dysregulated in cardiomyocytes. We defined a gene expression signature potentially driven by androgen receptor signaling in cardiomyocytes from individuals with AF. Cell-type-specific gene expression modules suggested an increase in T cell and a decrease in adipocyte and neuronal cell gene expression in AF. Lastly, we showed that reducing NR4A1 expression, a marker of a poorly characterized human atrial fibroblast subtype, fibroblast activation markers, extracellular matrix remodeling and cell proliferation decreased.
- 1 August 2024
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 17 (4) , e004614
Rare Variant in MRC2 Associated With Familial Supraventricular Tachycardia and Wolff-Parkinson-White Syndrome
BACKGROUND: Accessory pathways are a common cause of supraventricular tachycardia (SVT) and can lead to sudden cardiac death in otherwise healthy children and adults when associated with Wolff-Parkinson-White syndrome. The goal of this study was to identify genetic variants within a large family with structurally normal hearts affected by SVT and Wolff-Parkinson-White syndrome and determine causality of the gene deficit in a corresponding mouse model. METHODS: Whole exome sequencing performed on 2 distant members of a 3-generation family in which multiple members were affected by SVT or Wolff-Parkinson-White pattern (preexcitation) on ECG identified MRC2 as a candidate gene. Serial electrocardiograms, intracardiac electrophysiology studies, echocardiography, optical mapping studies, and histology were performed on both Mrc2 mutant and WT (wild-type) mice. RESULTS: A rare HET (heterozygous) missense variant c.2969A>G;p.Glu990Gly (E990G) in MRC2 was identified as the leading candidate gene variant segregating with the cardiac phenotype following an autosomal-dominant Mendelian trait segregation pattern with variable expressivity. In vivo electrophysiology studies revealed reentrant SVT in E990G mice. Optical mapping studies in E990G mice demonstrated abnormal retrograde conduction, suggesting the presence of an accessory pathway. Histological analysis of E990G mouse hearts showed a disordered ECM (extracellular matrix) in the annulus fibrosus. Finally, Mrc2 knockdown in human cardiac fibroblasts enhanced accelerated cell migration. CONCLUSIONS: This study identified a rare nonsynonymous variant in the MRC2 gene in individuals with familial reentrant SVT, Wolff-Parkinson-White ECG pattern, and structurally normal hearts. Furthermore, Mrc2 knock-in mice revealed an increased incidence of reentrant SVT and bypass tract formation in the setting of preserved cardiac structure and function.
- 1 August 2024
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 17 (4) , e004614
Rare Variant in MRC2 Associated With Familial Supraventricular Tachycardia and Wolff-Parkinson-White Syndrome
BACKGROUND: Accessory pathways are a common cause of supraventricular tachycardia (SVT) and can lead to sudden cardiac death in otherwise healthy children and adults when associated with Wolff-Parkinson-White syndrome. The goal of this study was to identify genetic variants within a large family with structurally normal hearts affected by SVT and Wolff-Parkinson-White syndrome and determine causality of the gene deficit in a corresponding mouse model. METHODS: Whole exome sequencing performed on 2 distant members of a 3-generation family in which multiple members were affected by SVT or Wolff-Parkinson-White pattern (preexcitation) on ECG identified MRC2 as a candidate gene. Serial electrocardiograms, intracardiac electrophysiology studies, echocardiography, optical mapping studies, and histology were performed on both Mrc2 mutant and WT (wild-type) mice. RESULTS: A rare HET (heterozygous) missense variant c.2969A>G;p.Glu990Gly (E990G) in MRC2 was identified as the leading candidate gene variant segregating with the cardiac phenotype following an autosomal-dominant Mendelian trait segregation pattern with variable expressivity. In vivo electrophysiology studies revealed reentrant SVT in E990G mice. Optical mapping studies in E990G mice demonstrated abnormal retrograde conduction, suggesting the presence of an accessory pathway. Histological analysis of E990G mouse hearts showed a disordered ECM (extracellular matrix) in the annulus fibrosus. Finally, Mrc2 knockdown in human cardiac fibroblasts enhanced accelerated cell migration. CONCLUSIONS: This study identified a rare nonsynonymous variant in the MRC2 gene in individuals with familial reentrant SVT, Wolff-Parkinson-White ECG pattern, and structurally normal hearts. Furthermore, Mrc2 knock-in mice revealed an increased incidence of reentrant SVT and bypass tract formation in the setting of preserved cardiac structure and function.